Latest news with #ChrisKirk
Yahoo
4 days ago
- Sport
- Yahoo
Kitayama, Grillo on the rise in FedExCup rankings
Rex Hoggard and Ryan Lavner examine how the 3M Open affected the FedExCup standings, where Kurt Kitayama and Emiliano Grillo moved inside the Top 70 while the straits get dire for Chris Kirk and Keith Mitchell.
Yahoo
15-07-2025
- Business
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Business Wire
15-07-2025
- Business
- Business Wire
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program,' said Chris Kirk, PhD, CEO and co-founder of Kezar. 'We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH.' Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'can,' 'should,' 'expect,' 'believe,' 'potential,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the 'Risk Factors' contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Yahoo
13-07-2025
- Sport
- Yahoo
South Africa's Potgieter grabs PGA Detroit lead
Aldrich Potgieter of South Africa grabbed the lead after the third round of the US PGA Tour Rocket Classic (Gregory Shamus) South Africa's 20-year-old Aldrich Potgieter birdied six of the first eight holes and seized a two-stroke lead after after Saturday's third round of the US PGA Tour's Rocket Classic. Potgieter, seeking his first PGA title in only his 20th tour start, reeled off five birdies in a row on the way to firing a bogey-free seven-under par 65 to stand on 19-under 197 after 54 holes at Detroit Golf Club. Advertisement "Being in contention is great," Potgieter said. "We're looking forward to tomorrow and maybe trying to just keep the ball in front, what we did today, hit a little bit more fairways and greens and if that putter just stays hot it will be good." Americans Max Greyserman, Chris Kirk, Andrew Putnam, Jake Knapp and Mark Hubbard shared second on 199 with South African Thriston Lawrence and Americans Michael Thorbjornsen and Jackson Suber on 200. "I just played really solid. Hit it really good. Gave myself a lot of chances," Knapp said. "With how bunched as this leaderboard is... you have to try to make as many birdies as you can." Potgieter, who managed his best PGA finish with a Mexico Open playoff loss to American Brian Campbell in February, began the day two adrift in a shootout. Advertisement The last group teed off with seven players sharing the lead on 14-under and 12 more only one stroke adrift. Potgieter took command early, blasting out of a bunker from 35 feet for birdie at the first then starting his birdie run with a putt from just inside eight feet at the fourth. He followed with a 33-foot birdie putt at the par-three fifth, dropped his approach inches from the hole at six to set up a tap-in birdie, sank an eight-foot birdie putt at the par-five seventh and made an 11-foot birdie putt at the eighth to reach 18-under with a three-stroke lead. Suber made back-to-back birdies at the ninth and 10th to reach 17-under and climb within one of the lead, but he fell back with a bogey at 12. Advertisement Potgieter, meanwhile, sank a birdie putt from just outside six feet at 13 to reach 19-under and restore a three-stroke edge. Knapp, who broke Potgieter's day-old course record of 62 with a 61 on Thursday, birdied the last three holes to shoot 66 and swipe a share of second. "I definitely thought I could get that course record back today with that six-under front nine," Potgieter said. "I was definitely trying to chase that course record again." Davis Thompson's 66 to finish on 202 was the first PGA round since 2020 to feature three front-nine eagles. He made three in the first eight, starting with an 80-yard hole-out from the fairway at the opening hole. Advertisement He followed with a 37-foot eagle putt at the par-five seventh and drove the green at the par-four eighth to set up a seven-foot eagle putt. "I don't think I've ever had that," Thompson said. "I've had three eagles in a round before, but I haven't had it all in nine holes." js/bb
Yahoo
04-07-2025
- Sport
- Yahoo
Aldrich Potgieter's Victory Proves Professional Golf's Next Generation Has No Fear
Aldrich Potgieter's Victory Proves Professional Golf's Next Generation Has No Fear originally appeared on Athlon Sports. The 18-foot birdie putt that rolled into the cup on the fifth playoff hole at Detroit Golf Club wasn't just another tournament-winning shot. It was a declaration. A statement from a generation of golfers who refuse to be intimidated by the bright lights, the pressure, or the supposed wisdom that says you need years of seasoning before you can compete at golf's highest levels. Advertisement Aldrich Potgieter, just 20 years old and barely old enough to legally drink in the United States, had just outlasted two seasoned professionals in Max Greyserman and Chris Kirk to claim his first PGA Tour victory at the Rocket Classic. The South African's celebration was pure joy — embracing his caddie, shaking hands with his competitors, then finding his father Heinrich for a hug that spoke to the journey they'd taken together from Pretoria to Perth to the winner's circle in Detroit. But Potgieter's triumph represents something far more significant than one young man's breakthrough moment. It's overwhelming evidence that professional golf is experiencing an extraordinary youth movement. One that's redefining what we thought we knew about experience, maturity, and the supposed necessity of paying your dues. The Myth of Weak Fields There's a narrative that persists among casual observers and cynical fans that today's PGA Tour fields are somehow "weaker" than in previous generations. The argument goes that without Tiger Woods in his prime, or with fewer household names in certain tournaments, the competition has been diluted. This perspective isn't just wrong — it's laughably ignorant of the reality of modern professional golf. Advertisement The truth is there's no such thing as a weak field in professional golf, only fields without the biggest names. Every player who tees it up on the PGA Tour has earned their way there through a gauntlet of qualifying that would have been unimaginable to previous generations. The depth of talent from top to bottom has never been greater, and the evidence is staring us right in the face every week. Potgieter's path to the PGA Tour is a perfect example. He didn't stumble into professional golf or get handed opportunities. He won The Amateur Championship at 17, became the youngest winner in Korn Ferry Tour history at 19, and earned his PGA Tour card by finishing 29th on the developmental tour's points list — a position he secured with a clutch final round when his entire future hung in the balance. A Generation Without Fear What makes Potgieter's generation different isn't just their talent — it's their fearlessness. These young players don't see the PGA Tour as some intimidating mountain to climb. They see it as their natural habitat, the place where they belong. Advertisement Consider the evidence from just the past few years. Scheffler won his first PGA Tour event at 25 and has since become the world's No. 1 player. Collin Morikawa won his first major championship at 23. Viktor Hovland claimed his first PGA Tour victory at 22. Xander Schauffele broke through at 23. The list goes on and on. And those are known names. Luke Clanton lines up a putt on the fourth green during the third round of the Rocket Mortgage Classic; June 28, 2025; Detroit, Aaron Doster-Imagn Images The emerging players — Luke Clanton, Nick Dunlap, Blades Brown, Michael Thorbjornsen, and countless others — arrive with an inherent fearlessness that sets them apart. While they'll inevitably face setbacks (Dunlap's early professional journey perfectly illustrates golf's inevitable ups and downs), these young competitors are already establishing themselves as legitimate forces in the professional game. On the LPGA Tour, the youth movement is even more pronounced. Nelly Korda won her first major at 22 and has since established herself as one of the game's dominant forces. Atthaya Thitikul turned professional at 17 and immediately began contending in major championships. Rose Zhang won her first LPGA event in just her second professional start after a decorated amateur career. She was a mere 20 years old. Advertisement These aren't anomalies or flukes. They represent a fundamental shift in how young players approach professional golf. Where previous generations might have been content to learn their craft gradually, today's young stars arrive with the expectation that they can compete immediately at the highest level. The Potgieter Template For me, what makes Potgieter's story particularly compelling is how it embodies all the elements that define this new generation of professional golfers. Fearless under pressure, as evidenced by his ability to close out his first PGA Tour victory in a marathon playoff. Physically gifted — leading the Korn Ferry Tour in driving distance at 336.5 yards and then the PGA Tour at 327.4 yards, all while maintaining the precision necessary to compete at the highest level. But here's what really matters: the kid has ice in his veins. When everything was on the line in that fifth playoff hole, Potgieter didn't fold. He stepped up and knocked in the putt that counted, showing the kind of nerves you used to only see from guys who'd been around the block a few times. Advertisement And let's talk about something else his win proves — just how good you have to be to even make it this far. The Korn Ferry Tour isn't some glorified mini-tour where guys are just happy to be there. It's a meat grinder where future stars cut their teeth, learning how to handle the heat when everything's on the line. Beyond the Headlines All the talk about big names and marquee players misses what's really happening out there — professional golf has never been this deep with talent. Week after week, players like Potgieter are showing up and proving that raw ability and hunger can beat reputation and résumé every single time. Look, I'm not trying to knock the veteran players here. They've earned their stripes and deserve respect. But what we're seeing is that golf's future couldn't be in better hands. These young guys aren't just gifted athletes — they show up ready to work, they handle themselves like pros, and they're not intimidated by anyone or anything. Advertisement Potgieter's breakthrough in Detroit? It's not going to be some rare feel-good story we talk about for years. This is the new reality. Young players stepping up and delivering in clutch moments is becoming routine, and frankly, that should get anyone who loves this game pretty excited about what's coming next. Aldrich Potgieter lines up a putt during the final round of the Rocket Mortgage Classic; June 29, 2025; Detroit, Aaron Doster-Imagn Images The New Normal As Potgieter celebrated his breakthrough victory in Detroit, he wasn't just winning a tournament — he was announcing his arrival as the latest member of a generation that's redefining what's possible in professional golf. At 20 years, 289 days old, he became the seventh-youngest PGA Tour winner since 1983 and the youngest South African ever to win on tour. Advertisement But more than the records and statistics, Potgieter's victory represents proof that the supposed "weak fields" critics love to complain about are actually deeper and more competitive than ever before. When a 20-year-old can step onto the PGA Tour and immediately compete with and defeat seasoned professionals, it's not a sign of weakness — it's evidence of a sport that's attracting and developing talent at an unprecedented level. The youth movement in professional golf isn't coming — it's here. And players like Aldrich Potgieter are leading the charge, one fearless shot at a time. Related: Allow Me to Introduce Myself Related: Let's Talk About Why Keegan Bradley Should Be Ryder Cup's First Playing Captain in 62 Years Related: How to Increase Club Head Speed With Your Driver This story was originally reported by Athlon Sports on Jul 2, 2025, where it first appeared.
